Evidence map›Paper›PMID 40768186›Full record

Trial reportLa Radiologia medica2025

Conventional vs. DEB vs. DSM: Which technique for palliative TACE in intermediate-stage HCC? Results on 70 patients in terms of efficacy and tolerance.

Francesco Giurazza, Claudio Carrubba, Ernesto Punzi, Raffaella Tortora, Marco Guarracino, Fiorella Brangi, Federica Falaschi, Carla Migliaccio, Fabio Corvino, Giovanni Vennarecci and 3 more

Abstract readClinical TrialComparative StudyMulticenter Study
PubMed Publisher
In one paragraph

Trial report in La Radiologia medica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Francesco GiurazzaVascular and Interventional Radiology Department, Cardarelli Hospital, Via Antonio Cardarelli 9, 80131, Naples, Italy. francescogiurazza@hotmail.it.ORCID http://orcid.org/0000-0002-9080-8833
Claudio CarrubbaVascular and Interventional Radiology Department, Cardarelli Hospital, Via Antonio Cardarelli 9, 80131, Naples, Italy.
Ernesto PunziInterventional Radiology Unit, Moscati Hospital, Contrada Amoretta, 83100, Avellino, Italy.
Raffaella TortoraHepatology Department, Cardarelli Hospital, Via Antonio Cardarelli 9, 80131, Naples, Italy.
Marco GuarracinoHepatology Department, Cardarelli Hospital, Via Antonio Cardarelli 9, 80131, Naples, Italy.
Fiorella BrangiOncology Department, Cardarelli Hospital, Via Antonio Cardarelli 9, 80131, Naples, Italy.
Federica FalaschiHepato-Biliary Surgery Deparment, Cardarelli Hospital, Via Antonio Cardarelli 9, 80131, Naples, Italy.
Carla MigliaccioHepato-Biliary Surgery Deparment, Cardarelli Hospital, Via Antonio Cardarelli 9, 80131, Naples, Italy.
Fabio CorvinoVascular and Interventional Radiology Department, Cardarelli Hospital, Via Antonio Cardarelli 9, 80131, Naples, Italy.
Giovanni VennarecciHepato-Biliary Surgery Deparment, Cardarelli Hospital, Via Antonio Cardarelli 9, 80131, Naples, Italy.
Giuseppe Giovanni Di CostanzoHepatology Department, Cardarelli Hospital, Via Antonio Cardarelli 9, 80131, Naples, Italy.
Giulio LombardiInterventional Radiology Unit, Moscati Hospital, Contrada Amoretta, 83100, Avellino, Italy.
Raffaella NiolaVascular and Interventional Radiology Department, Cardarelli Hospital, Via Antonio Cardarelli 9, 80131, Naples, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis study aims to compare palliative cTACE, DEB-TACE and DSM-TACE in patients affected by HCC in intermediate BCLC stage in terms of efficacy and patient tolerance. MATERIALS AND

methodsPatients treated with palliative TACE were prospectively enrolled in two centers during 9 months. Procedures were performed superselectively in all patients. Inclusion criteria were: HCC diagnosis, intermediate BCLC stage, portal tree patency, preserved hepatic-renal-coagulation functions, palliative procedural aim, follow-up available up to 6-month post-TACE intervention. Exclusion criteria were: previous TACE treatments, alone or in combination with ablation in the same session, ascites, bilirubin > 2mg/dL, age < 18years, bridge to transplant procedural aim, concomitant infectious diseases. Primary endpoint was to compare efficacy and patients tolerance among the 3 different TACE techniques; secondary endpoint was to compare post-procedural complications occurrence.

resultsSeventy patients were included and divided into three groups according to the TACE technique: 24 were treated with cTACE, 25 with DEB-TACE, 21 with DSM-TACE. According to mRECIST criteria at 1-, 3- and 6-month follow-up, DEB-TACE presented better local response rates but without statistically significant differences. Patients treated with DSM-TACE showed significantly better tolerance, considering post-procedural transaminases and INR values together with clinical adverse events occurrence monitored up to 7 days. There were no differences in post-procedural complications and no major complications occurred.

conclusionsIn this study, in patients with intermediate-stage HCC undergoing palliative treatments, no significant differences emerged comparing cTACE, DEB-TACE and DSM-TACE in terms of procedural efficacy; however, patients treated with DSM-TACE showed significant better procedural tolerance.

Indexed as

Carcinoma, HepatocellularChemoembolization, TherapeuticLiver NeoplasmsPalliative CareAgedFemaleHumansMaleMiddle AgedNeoplasm StagingProspective StudiesTreatment OutcomecTACEDEB-TACEDSM-TACEEfficacyHCCTolerance

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.